

1st September, 2023

The Dy. General Manager (Listing Dept.)
BSE Limited
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Clarification / Information on news item

This is with reference to the email received from BSE, bearing reference no. L/SURV/ONL/RV/VK/ (2023-2024)/ 30 and the letter received from NSE, bearing reference no. NSE/CM/Surveillance/13359, each dated August 31, 2023, seeking clarification/ confirmation in respect of the news item dated August 31, 2023 that appeared on “*Channels-ET NOW*” carrying the caption - “*Torrent Pharma is in talks to acquire Cipla Ltd.*”.

The Company has noted that the news item refers to a potential sale of shares by its promoters pertaining to their involvement in the acquisition of Cipla’s shares. As a policy, the Company does not comment on speculative reports in the absence of verified data.

There is currently no information which requires disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**Listing Regulations**”). Considering that the shares of the Company are freely traded on the stock exchanges, the Company will not be in a position to comment on the movement in its share price.

If and when any proposal warranting a disclosure is considered by the board of directors of the Company, the Company shall promptly comply with the disclosure obligations under Regulation 30 of the Listing Regulations.

Thanking you,

Yours Sincerely,
For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI
COMPANY SECRETARY

TORRENT PHARMACEUTICALS LIMITED

CIN: L24230GJ1972PLC002126

Reg.Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,
www.torrentpharma.com, Email Id: investorservices@torrentpharma.com